[Spirapril - a new long-acting ACE inhibitor: efficacy and safety in patients with arterial hypertension in combination with diabetes mellitus and impaired kidney function].
OBJECTIVE
To examine effectiveness and safety of quadropril.


METHODS
Changes in blood pressure (BP), heart rate (HR), levels of glucose, potassium and creatinine, creatinine clearance were studied in 120 patients (48 males and 72 females, mean age 60.6 +/- 0.7 years) with mild to moderate arterial hypertension (AH) with average duration 13.8 +/- 0.7 years. The patients were divided into 3 groups: with AH (n = 40), AH + noninsulindependent diabetes mellitus (DM) (n = 43), AH and nephropathy (n = 37). 8-week treatment was performed with a standard dose of 6 mg/day (1 tablet of quadropril). Control examinations were made 2, 4 and 8 weeks after the treatment.


RESULTS
After 8 weeks of treatment a decrease in systolic blood pressure in AH group was 24.0 +/- 3.0 mm Hg and in diastolic blood pressure 16.3 +/- 1.3 mm Hg (P < 0.001). In the group with DM this decrease was 22.4 +/- 2.8 mm Hg and 15.7 +/- 1.4 mm Hg (p < 0.001), respectively. In the group with nephropathy this decrease was 26.4 +/- 2.4 and 16.5 +/- 1.3 mm Hg (p < 0.001), respectively. Heart rate changed significantly only in diabetics: from 75.1 +/- 1.7 to 72.9 +/- 1.3 beats/min. Biochemical parameters in the hypertensive and diabetic patients did not change significantly. In the nephropathy group there was a significant decrease in creatinine and increase in creatinine clearance. Their level of glucose and potassium changed insignificantly.


CONCLUSIONS
The treatment with quadropril results in a significant decrease in blood pressure, does not influence parameters of carbohydrate metabolism, improves nitrogen eliminating function of the kidneys.
Iakusevich
V V
VV
Mozheĭko
M E
ME
Paliutin
Sh Kh
ShKh
Berezina
M Iu
MIu
Martsevich
S Iu
SIu
Shal'nova
S A
SA
Deev
A D
AD
Kutishenko
N P
NP
Alimova
E V
EV
Koniakhina
I P
IP
Semenova
Iu E
IuE
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D003404:Creatinine / Q000097:blood / Q000652:urine; D003692:Delayed-Action Preparations; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D004656:Enalapril / Q000008:administration & dosage* / Q000031:analogs & derivatives; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012449:Safety; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D001786:Blood Glucose; D003692:Delayed-Action Preparations; D004656:Enalapril; C052555:spirapril; D003404:Creatinine
Spirapril - novyĭ ingibitor angiotenzinprevrashchaiushchego fermenta dlitel'nogo deĭstviia: éffektivnost' i bezopasnost' u bol'nykh arterial'noĭ gipertonieĭ v sochetanii s sakharnym diabetom i narushennoĭ funktsieĭ pochek.